Humana Inc. (NYSE:HUM) had its price objective cut by Morgan Stanley from $276.00 to $270.00 in a research note released on Thursday morning. They currently have an overweight rating on the insurance provider’s stock.

Several other equities research analysts have also commented on the company. Royal Bank Of Canada reissued a sector perform rating and set a $242.00 price target (down previously from $245.00) on shares of Humana in a research note on Thursday. Credit Suisse Group assumed coverage on Humana in a research note on Thursday, November 2nd. They set a neutral rating and a $256.00 price target on the stock. Zacks Investment Research lowered Humana from a strong-buy rating to a hold rating in a research note on Tuesday, October 17th. BMO Capital Markets assumed coverage on Humana in a research note on Monday, October 16th. They set an outperform rating and a $300.00 price target on the stock. Finally, Jefferies Group LLC reissued a hold rating and set a $257.00 price target on shares of Humana in a research note on Friday, October 13th. Thirteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average price target of $252.81.

Shares of Humana (NYSE HUM) traded down $3.07 during trading hours on Thursday, hitting $244.39. The stock had a trading volume of 1,265,400 shares, compared to its average volume of 1,118,081. The stock has a market cap of $34,913.55, a price-to-earnings ratio of 20.85, a price-to-earnings-growth ratio of 1.58 and a beta of 0.91. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.61 and a quick ratio of 1.65. Humana has a fifty-two week low of $186.25 and a fifty-two week high of $264.56.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 8th. The insurance provider reported $3.39 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.27 by $0.12. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $13.41 billion. Humana had a return on equity of 15.99% and a net margin of 3.49%. The company’s quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.18 EPS. sell-side analysts expect that Humana will post 11.64 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Humana Inc. (HUM) PT Lowered to $270.00 at Morgan Stanley” was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.watchlistnews.com/humana-inc-hum-pt-lowered-to-270-00-at-morgan-stanley/1698474.html.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 26th. Shareholders of record on Friday, December 29th will be issued a $0.40 dividend. The ex-dividend date is Thursday, December 28th. This represents a $1.60 annualized dividend and a yield of 0.65%. Humana’s dividend payout ratio (DPR) is presently 12.59%.

In other news, insider William Kevin Fleming sold 3,071 shares of the business’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $250.98, for a total transaction of $770,759.58. Following the completion of the sale, the insider now directly owns 7,681 shares of the company’s stock, valued at approximately $1,927,777.38. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Elizabeth D. Bierbower sold 9,786 shares of the business’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $259.00, for a total transaction of $2,534,574.00. Following the sale, the insider now directly owns 18,042 shares of the company’s stock, valued at $4,672,878. The disclosure for this sale can be found here. Insiders have sold a total of 20,660 shares of company stock valued at $5,319,600 over the last three months. Corporate insiders own 0.80% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Koch Industries Inc. purchased a new stake in shares of Humana during the 2nd quarter valued at $404,000. Adviser Investments LLC purchased a new stake in shares of Humana during the 3rd quarter valued at $635,000. Teachers Advisors LLC grew its stake in shares of Humana by 31.6% during the 2nd quarter. Teachers Advisors LLC now owns 630,835 shares of the insurance provider’s stock valued at $151,792,000 after buying an additional 151,603 shares during the period. Prisma Capital Partners LP purchased a new stake in shares of Humana during the 2nd quarter valued at $7,122,000. Finally, Federated Investors Inc. PA grew its stake in shares of Humana by 608.1% during the 2nd quarter. Federated Investors Inc. PA now owns 34,626 shares of the insurance provider’s stock valued at $8,331,000 after buying an additional 29,736 shares during the period. 95.88% of the stock is owned by institutional investors.

About Humana

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.